Novo Nordisk is under fresh scrutiny as analysts adjust their price targets, with a fair value estimate moving from DKK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results